{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:52:15Z","timestamp":1776185535189,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"am","delay-in-days":316,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.lungcan.2020.04.025","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T22:19:18Z","timestamp":1588630758000},"page":"71-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Ongoing challenges of using immunotherapy in special populations: Poor performance status patients, elderly patients, and people living with HIV"],"prefix":"10.1016","volume":"145","author":[{"given":"Val\u00e9rie","family":"Gounant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armelle","family":"Lavol\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Quoix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.lungcan.2020.04.025_bib0005","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/JTO.0b013e3181622c17","article-title":"Prevalence of poor performance status in lung cancer patients: implications for research","volume":"3","author":"Lilenbaum","year":"2008","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2020.04.025_bib0010","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1200\/JCO.2008.18.7658","article-title":"First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy","volume":"27","author":"Inoue","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2020.04.025_bib0015","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jtho.2017.02.012","article-title":"Alectinib for patients with ALK rearrangement-positive non-small cell lung cancer and a poor performance status (Lung Oncology Group in Kyushu 1401)","volume":"12","author":"Iwama","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.04.025_bib0020","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejca.2019.11.019","article-title":"CheckMate 171: a phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS2 and elderly population","volume":"127","author":"Felip","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2020.04.025_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30033-3","article-title":"Pembrolizumab in patients with non-small-cell lung cancer of performans status 2 (PePS2): a single arm, phase 2 trial","author":"Middleton","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"9","key":"10.1016\/j.lungcan.2020.04.025_bib0030","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.jtho.2019.05.010","article-title":"Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non-small cell lung Cancer, Including patients aged 70 years or older or with poor performance status (CheckMate 153)","volume":"14","author":"Spigel","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2020.04.025_bib0035","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1016\/j.jtho.2019.08.424","article-title":"CheckMate 817 : first-line Nivolumab + ipilimumab in patients with ECOG PS 2 and other special populations with advanced NSCLC","volume":"14","author":"Barlesi","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"November (19)","key":"10.1016\/j.lungcan.2020.04.025_bib0040","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"KEYNOTE-024 investigators. Pembrolizumab versus chemotherapy for PD-L1-Positive non-small-Cell lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"November (21)","key":"10.1016\/j.lungcan.2020.04.025_bib0045","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2020.04.025_bib0050","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00310-2017","article-title":"Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major leukocytosis following nivolumab treatment","volume":"50","author":"Pluvy","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"9","key":"10.1016\/j.lungcan.2020.04.025_bib0055","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/j.jtho.2019.04.010","article-title":"Rapid response to pembrolizumab in a critically ill mechanically ventilated patient with new diagnosis of NSCLC","volume":"14","author":"McLoughlin","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.04.025_bib0060","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.32782","article-title":"Cancer. performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors","author":"Petrillo","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2020.04.025_bib0065","first-page":"1349","article-title":"Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: an interim analysis","volume":"17","author":"Bonomi","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.lungcan.2020.04.025_bib0070","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ctrv.2017.08.003","article-title":"Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: does age really matter?","volume":"60","author":"Ferrara","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"17","key":"10.1016\/j.lungcan.2020.04.025_bib0075","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2020.04.025_bib0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10027","key":"10.1016\/j.lungcan.2020.04.025_bib0085","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"10066","key":"10.1016\/j.lungcan.2020.04.025_bib0090","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.lungcan.2020.04.025_bib0095","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S1470-2045(18)30673-9","article-title":"Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study","volume":"19","author":"Barlesi","year":"2018","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2020.04.025_bib0100","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1053\/j.seminoncol.2018.08.007","article-title":"FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1\/PD-L1 blocking antibodies","volume":"45","author":"Marur","year":"2018","journal-title":"Semin. Oncol."},{"issue":"10030","key":"10.1016\/j.lungcan.2020.04.025_bib0105","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.lungcan.2020.04.025_bib0110","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-Positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.lungcan.2020.04.025_bib0115","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.lungcan.2020.04.025_bib0120","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2020.04.025_bib0125","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.lungcan.2019.08.030","article-title":"Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer","volume":"137","author":"Galli","year":"2019","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2020.04.025_bib0130","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.21037\/jtd.2019.12.46","article-title":"Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer","volume":"12","author":"Masuda","year":"2020","journal-title":"J. Thorac. Dis."},{"issue":"7","key":"10.1016\/j.lungcan.2020.04.025_bib0135","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2020.04.025_bib0140","doi-asserted-by":"crossref","first-page":"F13","DOI":"10.1097\/QAD.0000000000002298","article-title":"Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience","volume":"33","author":"Spano","year":"2019","journal-title":"AIDS"},{"issue":"9","key":"10.1016\/j.lungcan.2020.04.025_bib0145","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-A phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol."},{"issue":"suppl 15","key":"10.1016\/j.lungcan.2020.04.025_bib0150","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1200\/JCO.2019.37.15_suppl.2501","article-title":"Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected","volume":"37","author":"Gonzalez-Cao","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2020.04.025_bib0155","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nm.4108","article-title":"International AIDS Society global scientific strategy: towards an HIV cure 2016","volume":"22","author":"Deeks","year":"2016","journal-title":"Nat. Med."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220303950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220303950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:42:25Z","timestamp":1759236145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220303950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":31,"alternative-id":["S0169500220303950"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.04.025","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ongoing challenges of using immunotherapy in special populations: Poor performance status patients, elderly patients, and people living with HIV","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}